

Safety Data Sheet (SDS) According to the OSHA Hazard Communication Standard 29 CFR 1910.1200

SECTION 1. Identification

Product identifier

Product No 14776

Product name Dexamethasone

Recommended use of the chemical and restrictions on use

Identified usesThis product is intended for research purposes only.

Manufacturer, importer, supplier

Manufacturer address Cell Signaling Technology, Inc.

3 Trask Lane Danvers, MA 01923 United States TEL: +1 978 867 2300

FAX: +1 978 867 2400 www.cellsignal.com support@cellsignal.com

Emergency telephone number In case of emergency call CHEMTREC 1-800-424-9300

SECTION 2. Hazard(s) identification

Classification

Email address

Website

This substance/mixture is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

Reproductive toxicity	Category 1B
Specific target organ toxicity - repeated exposure (STOT RE)	Category 2

GHS Label elements, including precautionary statements



Signal Word Danger

Hazard statement(s)

May damage fertility or the unborn child. May cause damage to organs through prolonged or repeated exposure.

Precautionary Statement(s)

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Use personal protective equipment as required. Do not breathe dust/fume/gas/mist/vapors/spray.

IF exposed or concerned: Get medical advice/attention.

Store locked up.

Dispose of contents/container to an approved waste disposal plant.

Supplementary Hazard Information

No information available.

Hazards not otherwise classified (HNOC)

Not applicable.

SECTION 3. Composition/information on ingredients

 Formula
 C22H29FO5

 Molecular Weight
 392.5 g/mol

Chemical nature Monoconstituent substance

Synonyms Dexamethasone;
Fluormethylprednisolone;

Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11ß,16a)-

Chemical Name	CAS No	Weight %
dexamethasone	50-02-2	100

SECTION 4. First-aid measures

Eye contact Rinse thoroughly with plenty of water, also under the eyelids. Keep eye wide open while

rinsing.

Skin contact Immediate medical attention is required. Wash off immediately with soap and plenty of

water removing all contaminated clothes and shoes.

Inhalation Immediate medical attention is required. Move to fresh air. If not breathing, give artificial

respiration.

Ingestion Do NOT induce vomiting. Immediate medical attention is required. Never give anything by

mouth to an unconscious person. Drink plenty of water.

Most important symptoms and effects, both acute and delayed

No information available.

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

Advice for emergency responders

General advice Immediate medical attention is required. Show this safety data sheet to the doctor in

attendance.

Protection of first-aidersUse personal protective equipment. Avoid contact with skin, eyes and clothing.

SECTION 5. Fire-fighting measures

Extinguishing media

Suitable Extinguishing Media Use extinguishing measures that are appropriate to local circumstances and the

surrounding environment.

Unsuitable Extinguishing Media CAUTION: Use of water spray when fighting fire may be inefficient.

Specific hazards arising from the chemical

No information available.

Explosion Data

Sensitivity to Mechanical Impact None. **Sensitivity to Static Discharge** None.

Protective Equipment and Precautions for Firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

SECTION 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Other information

Ensure adequate ventilation. No information available.

Environmental precautions

Do not flush into surface water or sanitary sewer system.

Methods and material for containment and cleaning up

Methods for containment Methods for cleaning up Prevent further leakage or spillage if safe to do so.

Use personal protective equipment. Cover powder spill with plastic sheet or tarp to minimize spreading and keep powder dry. Take up mechanically and collect in suitable container for disposal. Avoid dust formation. Clean contaminated surface thoroughly.

SECTION 7. Handling and storage

Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice.

Conditions for safe storage, including any incompatibilities

Technical measures/Storage

conditions

Packaging material No information available.

Incompatible products

None known based on information supplied.

SECTION 8. Exposure controls/personal protection

Keep containers tightly closed in a dry, cool and well-ventilated place.

Control parameters

Appropriate engineering controls

Showers, eyewash stations, and ventilation systems.

Individual protection measures, such as personal protective equipment

Personal protective equipment (PPE) needs to be selected depending on the implemented engineering controls, frequency/duration of work activities and the concentrations of the hazardous substance.

Eye/face protection Skin and body protection Respiratory protection Tightly fitting safety goggles. Wear protective gloves/clothing.

If exposure limits are exceeded or irritation is experienced, NIOSH/MSHA approved respiratory protection should be worn. Positive-pressure supplied air respirators may be required for high airborne contaminant concentrations. Respiratory protection must be

Hygiene measures

provided in accordance with current local regulations.

When using, do not eat, drink or smoke. Provide regular cleaning of equipment, work area and clothing. Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. Keep away from food, drink and animal feeding stuffs.

SECTION 9. Physical and chemical properties

Information on basic physical and chemical properties

Physical state Solid

AppearanceCrystalline powderColorWhite, light creamOdorSlightOdor ThresholdNo information available

Property Values Remarks Method

pH No information available

Melting point/freezing point 262-264 °C

Initial boiling point and boiling

range Flash point

Evaporation rate

Flammability (solid, gas)

Upper flammability limit

Lower flammability limit

Vapor pressure

Vapor density

Relative density

No information available

Solubility Soluble in water @ 89.0 mg/mL @ 25 °C soluble

Solubility in other solvents
Partition coefficient: n-octanol/waterNo information available
Autoignition temperature
Decomposition temperature
Viscosity
No information available

Other information

Softening point No information available

Molecular Weight 392.5 g/mol

VOC contentNo information availableDensityNo information available.Bulk Density VALUENo information available.

SECTION 10. Stability and reactivity

Reactivity

No information available.

Chemical stability

Stable under recommended storage conditions.

Possibility of hazardous reactions

Hazardous reactions None under normal processing. Hazardous polymerization None under normal processing.

Conditions to Avoid

No information available.

Incompatible Materials

None known based on information supplied.

Hazardous Decomposition Products

None under normal use. May emit toxic fumes under fire conditions. Hydrogen fluoride.

SECTION 11. Toxicological information

Information on likely routes of exposure

Inhalation of particulates may cause mechanical irritation to upper respiratory tract. Inhalation

Contact with eyes may cause mechanical irritation. Eye contact May be absorbed through the skin in harmful amounts. Skin contact

Ingestion Target Organ Effects. Reproductive Toxicity.

Information on toxicological effects

This material should only be handled by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals. It should be borne in mind that the toxicological and physiological properties of this compound is not well defined.

Chemical Name	LD50 Oral	LD50 Dermal	LC50 Inhalation
dexamethasone	3 g/kg (Rat)	-	-

Delayed and immediate effects as well as chronic effects from short and long-term exposure

No information available.

Symptoms No information available. Sensitization No information available.

Mutagenic effects Not mutagenic in AMES Test. Negative in the mouse micronucleus test.

No component of this product present at levels greater than or equal to 0.1% is identifiable Carcinogenicity

as probable, possible or confirmed carcinogen by IARC, ACGIH, NTP, or OSHA.

Reproductive toxicity

Glucocorticoids may cause fetal damage when administered to pregnant women. One retrospective study of 260 women who received pharmacologic dosages of glucocorticoids during pregnancy revealed 2 instances of cleft palate, 8 stillbirths, 1 spontaneous abortion, and 15 premature births. Another study reported 2 cases of cleft palate in 86 births. Occurrence of cleft palate in these studies is higher than in the general population but could have resulted from the underlying diseases as well as from the steroids. Other fetal abnormalities that have been reported following glucocorticoid administration in pregnant women include hydrocephalus and gastroschisis.

Topical ocular administration of 0.15% dexamethasone (0.375 mg/kg/day) on gestational days 10 to 13 produced embryofetal lethality and a high incidence of cleft palate in mice. In rabbits, topical ocular administration of 0.1% dexamethasone throughout organogenesis (0.13 mg/kg/day, on gestational day 6 followed by 0.20 mg/kg/day on gestational days 7-18) produced intestinal anomalies, intestinal aplasia, gastroschisis and hypoplastic kidneys. In oral teratogenicity studies with rats using dose levels ranging from 10 to 1250/kg bw/day, maternal toxicity was found at 50 µg/kg bw/day and above. At doses at and above 1000 µg/kg bw/day, dexamethasone caused structural malformations (hydrops fetalis, cleft palate). Thymus involution and a decrease in body weight were observed in fetuses,

resulting in an overall NOEL for embryotoxicity in rats of 10 µg/kg bw/day.

STOT - single exposure STOT - repeated exposure

Following repeated oral administration of dexamethasone to rats and dogs in short-term toxicity studies the main target organs were the thymus and the adrenal gland.

Corticosteroid concentrations in plasma and hepatic glycogen were reduced, whereas serum lipid levels were increased. In rats dosed orally with 0.3, 1, 3, 10, 30, or 100 µg dexamethasone/kg bw/day for 90 days, thymus involution and morphological changes in the adrenal gland and a decrease in corticosterone and white blood cell counts were observed

in male and female rats at doses above 10 µg/kg bw/day.

Target Organ Effects Liver, Thymus, Reproductive system, Endocrine system.

Neurological effectsNo information available.Aspiration HazardNo information available.

SECTION 12. Ecological information

Ecotoxicity

Persistence and degradability
Bioaccumulation

No information available.
Not likely to bioaccumulate.

Mobility Is predicted to have low mobility in the environment

Chemical Name	Octanol-Water Partition Coefficient
dexamethasone	1.83

Other adverse effects

No information available.

SECTION 13. Disposal considerations

Waste Disposal Methods

Should not be released into the environment.

Disposal considerations

Do not empty into drains; dispose of this material and its container in a safe way.

SECTION 14. Transport information

This material is not subject to regulation as a hazardous material for shipping.

SECTION 15. Regulatory information

North American Inventory Listing

Chemical Name	TSCA 8(b)	TSCA 12(b)	DSL	NDSL
dexamethasone	Listed	Not Listed	Not Listed	Listed

Canadian Workplace Hazardous Materials Information System (WHMIS) Classification

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazard Categories

Acute Health Hazard No
Chronic Health Hazard Yes
Fire Hazard No
Sudden Release of Pressure Hazard No

Reactive Hazard No

Clean Water Act

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

California Proposition 65

This product does not contain any Proposition 65 chemicals.

U.S. State Right-to-Know Regulations

This product does not contain any substances regulated under applicable state right-to-know regulations

U.S. FIFRA Label Information

This product does not contain any substances regulated as pesticides.

US Commerce Department - Export Administration Regulations Information

This product does not contain any substances regulated under the Chemical Weapons Convention (CWC).

U.S. Drug Enforcement Administration Information

This product does not contain any substances regulated under the DEA.

SECTION 16. Other information

Issuing Date: 2015-01-16 **Revision Date**: 2017-08-08

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

End of Safety Data Sheet